The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1448464
This article is part of the Research Topic The Immune Infiltrate as a Paradigm Model to Study the Biology and Novel Therapeutic Approaches in Sarcomas, volume II View all 5 articles
Development and validation of a novel immune-r elated pr ognostic model and the potential metastatic mechanism in synovial sar coma
Provisionally accepted
Yufeng Huang
1,2*
Ming Gong
1,2
Jiaming Lin
1,2
Qinglian Tang
1,2
Hongmin Chen
1,2
Jinxin Hu
1,2
Chuangzhong Deng
1,2
Anfei Huang
1,2
Huixiong Feng
1,2
Guohui Song
1,2
Huaiyuan Xu
1,2
Jinchang Lu
1,2
Xiaojun Zhu
1,2
Wang Jin
1,2- 1 Department of Musculoskeletal Oncology, Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China
- 2 State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center (SYSUCC), Guanghzou, Guangdong, China
Several clinical trials have shown that immunotherapy plays a pivotal role in the treatment of patients with metastatic synovial sarcoma. Immune-related genes (IRGs) have been demonstrated to predict the immunotherapy response in certain malignant tumours. However, the clinical significance of IRGs in patients with synovial sarcoma(SS) is still unclear. We first combined the immune-related ImmPort gene set to search for SS related to metastatic and differentially expressed immune-related genes (DEIRGs) in the GSE40021 dataset from the GEO database. The soft tissue sarcoma database in TCGA was used for univariate Cox regression analyses to identify DEIRGs that were related to overall survival and to build an immune-related prognostic assessment model. The study screened a total of six DEIRGs that were closely related to prognosis in metastatic SS. Further analysis showed that there was no significant difference in the expression of several immune checkpoints between the two groups in the GSE40021 data. Moreover, the GREM2 and CTSS genes were significantly expressed in metastatic patients. Further verification of clinical SS tissues from our centre by RT-qPCR analysis demonstrated reduced infiltration of activated NK cells and macrophages but increased M2-type macrophages in metastatic patients. Together, our study successfully constructed an immune-related prognostic assessment model and probably explains the poor efficacy of PD-1 inhibitors for SS patients. The research deepens our understanding of the tumor immune microenvironment and proposes a new immune mechanism for metastatic SS.Early intervention and reversal of immunosuppressive microenvironmental changes are expected to delay metastasis and improve survival.Keywor ds: synovial sarcoma, immune-related genes, immune checkpoints, prognosis, tumour microenvironment
Keywords: synovial sarcoma (SS), immune-related genes, Immune checkpoints (ICPs), prognosis, tumour microenvironment (TME)
Received: 13 Jun 2024; Accepted: 22 Nov 2024.
Copyright: © 2024 Huang, Gong, Lin, Tang, Chen, Hu, Deng, Huang, Feng, Song, Xu, Lu, Zhu and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yufeng Huang, Department of Musculoskeletal Oncology, Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.